0001213900-26-048064.txt : 20260427 0001213900-26-048064.hdr.sgml : 20260427 20260427165816 ACCESSION NUMBER: 0001213900-26-048064 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20260421 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Material Modifications to Rights of Security Holders ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20260427 DATE AS OF CHANGE: 20260427 FILER: COMPANY DATA: COMPANY CONFORMED NAME: InMed Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001728328 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39685 FILM NUMBER: 26901835 BUSINESS ADDRESS: STREET 1: 1445-885 WEST GEORGIA ST. CITY: VANCOUVER STATE: A1 ZIP: V6C 3E8 BUSINESS PHONE: (604) 669-7207 MAIL ADDRESS: STREET 1: 1445-885 WEST GEORGIA ST. CITY: VANCOUVER STATE: A1 ZIP: V6C 3E8 8-K 1 ea0287728-8k_inmed.htm CURRENT REPORT
false 0001728328 A1 BC 0001728328 2026-04-21 2026-04-21 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): April 21, 2026

 

INMED PHARMACEUTICALS INC.

(Exact Name of Company as Specified in Charter)

 

British Columbia   001-39685   98-1428279
(State or Other Jurisdiction
of Incorporation)		   (Commission File Number)   (IRS Employer
Identification No.)

 

InMed Pharmaceuticals Inc.

Suite 1445 - 885 W. Georgia Street,

Vancouver, B.C.

Canada

   V6C 3E8
(Address of Principal Executive Offices)   (Zip Code)

 

Company’s telephone number, including area code: (604) 669-7207

 

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange
on which registered
Common Shares, no par value   INM   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company  ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

 

 

 

Item 1.01 Entry into a Material Definitive Agreement.

 

Preferred Investment Option Amending Agreement with Sabby Volatility Warrant Master Fund, Ltd.

 

As previously reported, pursuant to the terms of the Preferred Investment Options dated October 26, 2023 and June 26, 2025 (together, the “Sabby Preferred Investment Options” and each a “Sabby Preferred Investment Option”), InMed Pharmaceuticals Inc. (the “Company”) provided Sabby Volatility Warrant Master Fund, Ltd. (“Sabby”) with the right to subscribe for and purchase from the Company, in the aggregate, up to 2,151,478 common shares in the capital of the Company at an exercise price per common share of $2.436, subject to adjustment (the “Sabby Exercise Price”). The Sabby Preferred Investment Options were offered in private placements pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and Regulation D promulgated thereunder.

 

On April 21, 2026, the Company entered into a Preferred Investment Option Amending Agreement (the “Sabby Preferred Investment Option Amending Agreement”) with Sabby to amend the Sabby Exercise Price contained in each Sabby Preferred Investment Option from $2.436 to $0.80.

 

The foregoing description of the Sabby Preferred Investment Option Amending Agreement is not complete and is qualified in its entirety by the full text of the Sabby Preferred Investment Option Amending Agreement, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K (this “Report”) and incorporated herein by reference.

 

Preferred Investment Option Amending Agreement with Affiliates of H.C. Wainwright & Co., LLC

 

As previously reported, pursuant to the terms of Preferred Investment Options dated November 21, 2022, October 26, 2023 and June 26, 2025 (together, the “Wainwright Preferred Investment Options” and each a “Wainwright Preferred Investment Option”), the Company provided three affiliates of H.C. Wainwright & Co., LLC (“Wainwright” and, such affiliates of Wainwright, the “Wainwright Parties” and each, a “Wainwright Party”) with the right to subscribe for and purchase from the Company, in the aggregate, up to 153,236 common shares in the capital of the Company (on a post-consolidation basis) at an exercise price per common share of $82.50, $20.75 and $3.2013 (in each case, on a post-consolidation basis), respectively, subject to adjustment in each case (together, the “Wainwright Exercise Prices”). The Wainwright Preferred Investment Options were offered in private placements pursuant to Section 4(a)(2) of the Securities Act and Regulation D promulgated thereunder.

 

On April 24, 2026, the Company entered into Preferred Investment Option Amending Agreements (the “Wainwright Preferred Investment Option Amending Agreements”) with each Wainwright Party to amend the Wainwright Exercise Prices contained in each Wainwright Preferred Investment Option to $0.80. 

 

The foregoing description of the Wainwright Preferred Investment Option Amending Agreements is not complete and is qualified in its entirety by the full text of the Wainwright Preferred Investment Option Amending Agreements, a copy of a form of which is filed as Exhibit 10.2 to this Report and incorporated herein by reference. The Wainwright Preferred Investment Option Amending Agreements are identical to each other except the names of the Wainwright Parties and the number of common shares that can be purchased by each Wainwright Party.

 

1

 

 

Item 3.03 Material Modification to Rights of Security Holders.

 

To the extent required by Item 3.03 of Form 8-K, the information contained in Item 1.01 of this Report is incorporated by reference herein.

 

Item 8.01 Other Events.

 

On April 27, 2026, the Company issued a press release announcing the amendments to the Sabby Preferred Investment Options and the Wainwright Preferred Investment Options. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein. The press release contains forward-looking statements and includes cautionary statements identifying important factors that could cause actual results to differ materially from those in the forward-looking statements. 

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits. 

 

Exhibit No.   Description
   
10.1   Sabby Preferred Investment Option Amending Agreement
10.2   Form of Wainwright Preferred Investment Option Amending Agreement
99.1   Press Release
104   Cover Page Interactive Data File (embedded within the Inline XBRL document and included as Exhibit 101)

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  INMED PHARMACEUTICALS INC.
   
Date: April 27, 2026 By: /s/ Eric A Adams
    Eric A Adams
President & CEO

 

3 

 

 

 

 EX-10.1 2 ea028772801ex10-1.htm SABBY PREFERRED INVESTMENT OPTION AMENDING AGREEMEN

Exhibit 10.1

 

preferred investment option AMENDING AGREEMENT

 

THIS PREFERRED INVESTMENT OPTION AMENDING AGREEMENT (the “Agreement”) is dated April 21, 2026 between:

 

SABBY VOLATILITY WARRANT MASTER FUND, LTD.

(the “Holder”)

 

-and-

 

INMED PHARMACEUTICALS INC.

(the “Company”).

 

WHEREAS:

 

(A)pursuant to the terms of Preferred Investment Options dated October 26, 2023 and June 26, 2025 (together, the “Preferred Investment Options”, and each, a “Preferred Investment Option”), the Company has provided the Holder with the right to subscribe for and purchase from the Company, in the aggregate, up to 2,151,478 Common Shares in the capital of the Company at an exercise price per Common Share of $2.436, subject to adjustment (the “Exercise Price”);

 

(B)the parties wish to amend the Exercise Price contained in each Preferred Investment Option, in each case in accordance with Section 5. l) thereof; and

 

(C)capitalized terms used but not defined herein shall have the meanings given to such terms in the Preferred Investment Options.

 

NOW THEREFORE, in consideration of the mutual covenants and agreements contained in this Agreement and other good and valuable consideration (the sufficiency and receipt of which are hereby acknowledged), the Holder and the Company agree as follows:

 

1.Section 2. b) of each Preferred Investment Option is, without any further action on the part of any Person, hereby amended by deleting “$2.436” and replacing it with “$0.80”.

 

2.For certainty, the parties hereto agree that, except as specifically provided herein, the terms and conditions of each Preferred Investment Option are hereby confirmed and continue in full force and effect.

 

3.All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof.

 

4.This Agreement shall enure to the benefit of and be binding upon the parties hereto and their respective legal representatives, heirs, executors, administrators, successors and assigns.

 

5.This Agreement may be executed in any number of separate counterparts and all such signed counterparts will together constitute one and the same agreement. To evidence its execution of an original counterpart of this Agreement, a party may send a copy of its signature on the execution page hereof to the other parties by facsimile or other means of recorded electronic transmission (including in PDF form) and such transmission shall constitute valid delivery of an executed copy of this agreement to the receiving party.

 

[Remainder of page intentionally left blank; signature page follows.]

 

 

 

 

The undersigned hereby agree to the terms set forth herein as of the date first written above.

 

  SABBY VOLATILITY WARRANT MASTER FUND, LTD.
   
  Per:  
      Name:
      Title:
       
  INMED PHARMACEUTICALS INC.
   
  Per:  
      Name:
      Title:

 

 

 

[Signature Page – Preferred Investment Option Amending Agreement]

 

 

 

 EX-10.2 3 ea028772801ex10-2.htm FORM OF WAINWRIGHT PREFERRED INVESTMENT OPTION AMENDING AGREEMENT

Exhibit 10.2

 

Form OF preferred investment option AMENDING AGREEMENT

 

THIS PREFERRED INVESTMENT OPTION AMENDING AGREEMENT (the “Agreement”) is dated April 24, 2026 between:

 

[   ]1

(the “Holder”)

 

-and-

 

INMED PHARMACEUTICALS INC.

(the “Company”).

 

WHEREAS:

 

(A)pursuant to the terms of Preferred Investment Options dated November 21, 2022, October 26, 2023, and June 26, 2025 (together, the “Preferred Investment Options”), the Company has provided the Holder with the right to subscribe for and purchase from the Company, in the aggregate, up to [ ]2 Common Shares (on a post-consolidation basis) in the capital of the Company at exercise prices per Common Share of $3.30 (or $82.50 on a post-consolidation basis), $1.03750 (or $20.75 on a post-consolidation basis), and $3.2013, respectively, subject to adjustment in each case (the “Exercise Price”);

 

(B)the parties wish to amend the Exercise Price contained in each Preferred Investment Option, in each case in accordance with Section 5. (l) thereof; and

 

(C)capitalized terms used but not defined herein shall have the meanings given to such terms in each Preferred Investment Option.

 

NOW THEREFORE, in consideration of the mutual covenants and agreements contained in this Agreement and other good and valuable consideration (the sufficiency and receipt of which are hereby acknowledged), the Holder and the Company agree as follows:

 

1.Section 2. (b) of each Preferred Investment Option is, without any further action on the part of any Person, hereby deleted in its entirety and replaced with:

 

“b) Exercise Price. The exercise price per share of Common Shares under this Preferred Investment Option shall be $0.80, subject to adjustment hereunder (the “Exercise Price”).”

 

2.For certainty, the parties hereto agree that, except as specifically provided herein, the terms and conditions of each Preferred Investment Option are hereby confirmed and continue in full force and effect.

 

3.All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof.

 

4.This Agreement shall enure to the benefit of and be binding upon the parties hereto and their respective legal representatives, heirs, executors, administrators, successors and assigns.

 

5.This Agreement may be executed in any number of separate counterparts and all such signed counterparts will together constitute one and the same agreement. To evidence its execution of an original counterpart of this Agreement, a party may send a copy of its signature on the execution page hereof to the other parties by facsimile or other means of recorded electronic transmission (including in PDF form) and such transmission shall constitute valid delivery of an executed copy of this agreement to the receiving party.

 

[Remainder of Page Intentionally Blank; Signature Page Follows]

 

 
1Each of the Wainright Preferred Investment Option Amending Agreements are identical except the name of the Wainright Party and the number of shares that can be purchased.
2Each of the Wainright Preferred Investment Option Amending Agreements are identical except the name of the Wainright Party and the number of shares that can be purchased.

 

 

 

 

The undersigned hereby agree to the terms set forth herein as of the date first written above.

 

     
    [  ]
     
  INMED PHARMACEUTICALS INC.
   
  Per:     
    Name:
    Title:

 

[Signature Page – Preferred Investment Option Amending Agreement]

 

 

 

 EX-99.1 4 ea028772801ex99-1.htm PRESS RELEASE

Exhibit 99.1

 

 

NASDAQ: INM

 

Suite 1445-885 West Georgia St.

Vancouver, BC, Canada V6C 3E8

Tel: +1.604.669.7207

Email: info@inmedpharma.com

www.inmedpharma.com

 

InMed Pharmaceuticals Amends Preferred Investment Options

 

Vancouver, BC – April 27, 2026 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announces that it has entered into amending agreements in respect of preferred investment options previously entered into with each of Sabby Volatility Warrant Master Fund, Ltd. (“Sabby”) and certain affiliates of H.C. Wainwright & Co., LLC (the “Wainwright Parties”).

 

As previously reported:

 

·pursuant to the terms of the preferred investment options dated October 26, 2023 and June 26, 2025 (together, the “Sabby Preferred Investment Options”), the Company provided Sabby with the right to subscribe for and purchase from the Company, in the aggregate, up to 2,151,478 common shares in the capital of the Company (on a post-consolidation basis) at an exercise price per common share of $2.436, subject to adjustment (the “Sabby Exercise Price”); and

 

·pursuant to the terms of the preferred investment options dated November 21, 2022, October 26, 2023 and June 26, 2025 issued to the Wainwright Parties (collectively, the “Wainwright Preferred Investment Options”, and together with the Sabby Preferred Investment Options, the “Preferred Investment Options”), the Company provided the Wainwright Parties with the right to subscribe for and purchase from the Company, in the aggregate, up to 153,236 common shares in the capital of the Company (on a post-consolidation basis) at exercise prices per common share of $82.50, $20.75 and $3.2013 (in each case, on a post-consolidation basis), respectively, subject to adjustment in each case (collectively, the “Wainwright Exercise Prices”).

 

The Company has entered into: (i) an amending agreement with Sabby in respect of the Sabby Preferred Investment Options to amend the Sabby Exercise Price to $0.80; and (ii) amending agreements with the Wainwright Parties in respect of the Wainwright Preferred Investment Options to amend the Wainwright Exercise Prices in the Wainwright Preferred Investment Options to $0.80.

 

Each of the Preferred Investment Options were offered in private placements pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, and Regulation D promulgated thereunder. No assurance can be given that any of the Preferred Investment Options will be exercised.

 

For further information, please see the Company's filings with the Securities and Exchange Commission, including the Company's Current Reports on Form 8-K filed with the Securities and Exchange Commission from time to time.

 

 

 

 

About InMed

 

InMed Pharmaceuticals is a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications. Together with our subsidiary BayMedica, we are a global leader in the manufacturing, development and commercialization of products based on rare cannabinoids and their proprietary, small molecule drug analogs. For more information, visit www.inmedpharma.com.

 

Investor Contact:

Colin Clancy

Vice President, Investor Relations

and Corporate Communications

T: +1.604.416.0999

E: ir@inmedpharma.com

 

Cautionary Note Regarding Forward-Looking Information:

 

This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities laws. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Without limiting the foregoing, forward-looking information in this news release includes, but is not limited to, statements about the exercise of the Preferred Investment Options prior to their expiration.

 

With respect to the forward-looking information contained in this news release, InMed has made numerous assumptions regarding, among other things: the ability to obtain all necessary regulatory approvals on a timely basis, or at all; and continued economic and market stability. While InMed considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies. Additionally, there are known and unknown risk factors which could cause InMed's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. A complete discussion of the risks and uncertainties facing InMed’s stand-alone business is disclosed in InMed’s Annual Report on Form 10-K, InMed’s Quarterly Report on Form 10-Q and other filings with the Security and Exchange Commission on www.sec.gov.

 

All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

 

 

 

 

 

 GRAPHIC 5 ea028772801_ex99-1img1.jpg GRAPHIC begin 644 ea028772801_ex99-1img1.jpg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end EX-101.SCH 6 inm-20260421.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 8 inm-20260421_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 9 inm-20260421_pre.xml XBRL PRESENTATION FILE XML 11 R1.htm IDEA: XBRL DOCUMENT v3.26.1
Cover
Apr. 21, 2026
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Apr. 21, 2026
Entity File Number 001-39685
Entity Registrant Name INMED PHARMACEUTICALS INC.
Entity Central Index Key 0001728328
Entity Tax Identification Number 98-1428279
Entity Incorporation, State or Country Code A1
Entity Address, Address Line One InMed Pharmaceuticals Inc.
Entity Address, Address Line Two Suite 1445 - 885 W. Georgia Street
Entity Address, City or Town Vancouver
Entity Address, State or Province BC
Entity Address, Country CA
Entity Address, Postal Zip Code V6C 3E8
City Area Code (604)
Local Phone Number 669-7207
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Shares, no par value
Trading Symbol INM
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 13 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 15 FilingSummary.xml IDEA: XBRL DOCUMENT 3.26.1 html 1 25 1 false 0 0 false 0 false false R1.htm 00000001 - Document - Cover Sheet http://inmed.com/role/Cover Cover Cover 1 false false All Reports Book All Reports ea0287728-8k_inmed.htm inm-20260421.xsd inm-20260421_lab.xml inm-20260421_pre.xml http://xbrl.sec.gov/dei/2025 true false JSON 18 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ea0287728-8k_inmed.htm": { "nsprefix": "INM", "nsuri": "http://inmed.com/20260421", "dts": { "inline": { "local": [ "ea0287728-8k_inmed.htm" ] }, "schema": { "local": [ "inm-20260421.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd", "https://xbrl.sec.gov/country/2025/country-2025.xsd", "https://xbrl.sec.gov/dei/2025/dei-2025.xsd", "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd" ] }, "labelLink": { "local": [ "inm-20260421_lab.xml" ] }, "presentationLink": { "local": [ "inm-20260421_pre.xml" ] } }, "keyStandard": 25, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 4, "http://xbrl.sec.gov/dei/2025": 4 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2025": 25 }, "report": { "R1": { "role": "http://inmed.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2026-04-21", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "ea0287728-8k_inmed.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2026-04-21", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "ea0287728-8k_inmed.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AmendmentDescription", "presentation": [ "http://inmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AmendmentFlag", "presentation": [ "http://inmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AnnualInformationForm", "presentation": [ "http://inmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://inmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CityAreaCode", "presentation": [ "http://inmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CountryRegion", "presentation": [ "http://inmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://inmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentAccountingStandard", "presentation": [ "http://inmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentAnnualReport", "presentation": [ "http://inmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://inmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://inmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentPeriodEndDate", "presentation": [ "http://inmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentPeriodStartDate", "presentation": [ "http://inmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentQuarterlyReport", "presentation": [ "http://inmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentRegistrationStatement", "presentation": [ "http://inmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://inmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentShellCompanyReport", "presentation": [ "http://inmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentTransitionReport", "presentation": [ "http://inmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentType", "presentation": [ "http://inmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://inmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressAddressLine1", "presentation": [ "http://inmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressAddressLine2", "presentation": [ "http://inmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressAddressLine3", "presentation": [ "http://inmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressCityOrTown", "presentation": [ "http://inmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressCountry", "presentation": [ "http://inmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://inmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://inmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://inmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCentralIndexKey", "presentation": [ "http://inmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://inmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://inmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://inmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityExTransitionPeriod", "presentation": [ "http://inmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityFileNumber", "presentation": [ "http://inmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityFilerCategory", "presentation": [ "http://inmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://inmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://inmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityPrimarySicNumber", "presentation": [ "http://inmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://inmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityRegistrantName", "presentation": [ "http://inmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityShellCompany", "presentation": [ "http://inmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntitySmallBusiness", "presentation": [ "http://inmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://inmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityVoluntaryFilers", "presentation": [ "http://inmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://inmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "Extension", "presentation": [ "http://inmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "LocalPhoneNumber", "presentation": [ "http://inmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "NoTradingSymbolFlag", "presentation": [ "http://inmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://inmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://inmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "PreCommencementTenderOffer", "presentation": [ "http://inmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "Security12bTitle", "presentation": [ "http://inmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "Security12gTitle", "presentation": [ "http://inmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "SecurityExchangeName", "presentation": [ "http://inmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "SecurityReportingObligation", "presentation": [ "http://inmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "SolicitingMaterial", "presentation": [ "http://inmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "TradingSymbol", "presentation": [ "http://inmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "WrittenCommunications", "presentation": [ "http://inmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 19 0001213900-26-048064-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-26-048064-xbrl.zip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ea0287728-8k_inmed_htm.xml IDEA: XBRL DOCUMENT 0001728328 2026-04-21 2026-04-21 false 0001728328 A1 BC 8-K 2026-04-21 INMED PHARMACEUTICALS INC. 001-39685 98-1428279 InMed Pharmaceuticals Inc. Suite 1445 - 885 W. Georgia Street Vancouver CA V6C 3E8 (604) 669-7207 false false false false Common Shares, no par value INM NASDAQ true false